Altimmune (ALT) Accumulated Expenses (2010 - 2026)

Altimmune (ALT) has 17 years of Accumulated Expenses data on file, last reported at $9.8 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 12.29% year-over-year to $9.8 million in Q1 2026; TTM through Mar 2026 was $9.8 million, a 12.29% increase from a year earlier, with the FY2025 full-year figure at $12.3 million, up 19.72% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $9.8 million, down from $12.3 million in the prior quarter.
• Over the last five years, Accumulated Expenses for ALT reached as high as $12.6 million in Q1 2022 and fell as low as $48000.0 in Q3 2022.
• Historically, Accumulated Expenses has averaged $6.2 million across 5 years, with a median of $7.5 million in 2024.
• Across the five-year window, Accumulated Expenses slumped 99.75% in 2022 and jumped 15006.12% in 2023, its largest moves.
• Year by year, Accumulated Expenses stood at $12.2 million in 2022, then slipped by 17.77% to $10.1 million in 2023, then advanced by 1.83% to $10.3 million in 2024, then gained by 19.72% to $12.3 million in 2025, then declined by 20.25% to $9.8 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $9.8 million in Q1 2026, $12.3 million in Q4 2025, and $2.4 million in Q3 2025.